Biological macromolecule-driven therapeutics in rheumatoid arthritis: Integrating drug delivery, regenerative medicine, and orthopedic repair.

Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting 0.5-1 % of the global population, leading to joint destruction, disability, and high socioeconomic costs. While conventional therapies like DMARDs and biologics have improved outcome…

Preview only. Read the full abstract at the source